Share the Video:

Regulatory considerations and opportunities

Tadeusz Hawrot, Natasia Poinsatte, Nicole Howell

Research using psychedelic drugs for therapeutic purposes has faced a number of regulatory obstacles unlike other treatments in the mental health field, including widespread skepticism and unfamiliarity among policymakers and regulators, limited government funding, and of course, Schedule 1 restrictions. In this panel, leaders of government and regulatory affairs offices from the psychedelic industry will share their stories about working with policymakers and administrators, and share their predictions for the future.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

The state of the psychedelic sector

Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.

Josh Hardman

PS2023 Business Policy and Advocacy Psychedelic Science Research Research and Science Social and Cultural

Patents, commons, and innovation in psychedelic drug development

Universities and companies are claiming intellectual property on psychedelic compounds, sparking dialogue on how patents may impact innovation and access to care in the psychedelic ecosystem. Explore economic and cultural

Jonathan Sporn, Sisi Li, Graham Pechenik, Retsina Meyer, Anne Donohoe

PS2023 Business Health Equity Policy and Advocacy Psychedelic Science Research Research and Science

Innovations in Global Healthcare and Lessons for Psychedelics

Elliot Cohen (Pillpack, Amazon) and Protik Basu (World Bank, UN, Helena) share insights on healthcare delivery, psychedelics industry, scaling challenges, and technology's role in patient care.

Andrew “Mo” Septimus, Protik Basu, Elliot Cohen

PS2023 Business Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research and Science

The evolving financial landscape for psychedelic medicine

Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.

Henry Elkus

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Research and Science

Updates from leading statewide regulatory initiatives - Colorado

Oregon’s Psilocybin Services Act and Colorado’s Natural Medicine Health Act are pioneering successful statewide initiatives regulating adult psychedelic substance use. Leaders discuss challenges and lessons learned in implementation.

Rev Veronica Lightning Horse P…, Ean Seeb, Hadas Alterman

PS2023 MDMA Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

Priorities for the next generation of psychedelic science

NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study

Joshua A Gordon

PS2023 Policy Policy and Advocacy Psychedelic Science Public Benefit Research Research and Science

Updates from leading statewide regulatory initiatives - Oregon

Oregon’s Psilocybin Services Act and Colorado’s Natural Medicine Health Act are pioneering successful statewide initiatives regulating adult psychedelic substance use, influencing drug policy reforms in eleven other states in 2023.

Angela E Albee, Sam Chapman

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research Research and Science Resources for Therapists

The State of Psychedelic Research Since 2017

Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.

Paul Summergrad, Tom Insel, Rachel Nuwer

PS2023 Policy Policy and Advocacy Psychedelic Science Research Research and Science Social and Cultural

Psychedelic policy approaches: from the visionary to the pragmatic

Discussion between experts on pragmatic frameworks, demographic considerations, and evidence-based practices shaping psychedelic policy reform for diverse contexts, addressing regulatory challenges and fostering nuanced understanding.

Tatiana Quintana, Melissa Lavasani, Logan Davidson

Regulatory considerations and opportunities

Become a MAPS Member with a monthly donation

Related Videos